Evaluation of Omarigliptin (MK-3102) in Obese Participants and in Participants With Type 2 Diabetes (MK-3102-004)

• Status: Completed
• Trial end date: 2010-05-11
• Target enrollment: 0
• Participant gender: All

Summary

This study will test the safety and tolerability of omarigliptin. It is hypothesized that administration of once-weekly omarigliptin in obese but otherwise healthy participants, and in obese participants with Type 2 diabetes (T2D) will be sufficiently safe and well tolerated to permit continued clinical investigation.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.

Criteria

Inclusion Criteria:

• obese (body mass index [BMI] ≥30 kg/m² and ≤40 kg/m²) male participants and female participants of non-childbearing potential

• has been diagnosed with T2D (Panel B)

• is not actively participating in a weight loss program

Exclusion Criteria:

• has a history of clinically-significant disease (other than T2D)

• has a history of cancer

• has estimated creatinine clearance ≤60 mL/min

• is unable to refrain from or anticipates the use of any prescription or non-prescription medication

• consumes excessive amounts of alcohol or caffeine

• has participated in a previous omarigliptin study